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At the end of 1990s, acute respiratory tract infections (ARTIs) were called the ‘forgotten pandemic’, with a clear
dichotomy between developing and industrialised countries in mortality and morbidity, the main outcomes
associated with ARTIs. This definition still applies 20 years later, when the introduction of new and safe antibiotics
and vaccines has certainly contributed to controlling the most life-threatening ARTIs, but has not had a major
impact on viral ARTIs in paediatric age. One functional approach to preventing and treating ARTIs is non-specifically
increasing the immune response or enhancing the children’s innate defence mechanisms. Different kinds of
biologically active substances – called immunostimulants – of natural and synthetic origins and with different
mechanisms of action have been introduced in some countries for the prevention of ARTIs in children. Recently,
research focused on one of these compounds, Pidotimod, has attempted to better clarify and define its mechanisms
of action both in vitro and in vivo. In this paper, we critically examine the most recent findings on Pidotimod.
Certainly the improvement of research methodology in the last 20 years and the acquired knowledge in various
fields of clinical immunology should be the starting point for research on Pidotimod. Preclinical research will be
essential to better understand the mechanisms of action of this compound. However, in vivo studies, especially
randomised control trials, will be necessary to establish the real efficacy of Pidotimod in the prevention of ARTIs
in paediatric age.
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At the end of 1990s, acute respiratory tract infections
(ARTIs) were called the ‘forgotten pandemic’, with a
clear dichotomy between developing and industrialised
countries in mortality and morbidity, the main outcomes
associated with ARTIs [1]. This definition still applies
20 years later, when the introduction of new and safe
antibiotics and vaccines has certainly contributed to
controlling the most life-threatening ARTIs, but have
not had a major impact on viral ARTIs. Viruses are the
main agents responsible for ARTIs during the paediatric
age and the high number of circulating virus and the
different viral sub-types result in a higher probability of
experiencing frequent ARTIs during childhood [2].
These epidemiological features besides the well-known
immaturity of the immune system during the first years
of life and the exposure to risk factors (air pollution,
parental tobacco smoke, daycare attendance) are mainly
responsible of the recurrence of ARTIs, and contribute* Correspondence: gianvincenzo.zuccotti@unimi.it
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distribution, and reproduction in any mediumto the incidence of recurrent respiratory infections
especially in the first 6 years of life [3-5].
Today, the socio-economical burden of ARTIs remains
high in industrialised countries. The pharmacological
cost of symptomatic drugs, antibiotics, the search for as-
sistance by a general practitioner, hospitalisation, as well
as specialist referral contribute to healthcare expenses
[6-8]. Moreover, indirect costs such as parental absences
from work and loss of productivity should not be
neglected [9]. In consideration of current epidemiological
and socio-economical data, there is a need for alternative
approaches to the most well-studied and known therapies.
One functional approach to preventing and treating
ARTIs is non-specifically increasing the immune response
or enhancing the child’s innate defence mechanisms.
Different kinds of biologically active substances – called
immunostimulants – of natural and synthetic origins and
with different mechanisms of action have been introduced
in some countries for the prevention of ARTIs in children
[10-13]. Concerning the real mechanisms of action,
efficacy and safety issues have discouraged their use inCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in the USA. Certainly most of studies on immunostimu-
lants were conducted many years ago and the methodo-
logical bias reported was not entirely insignificant. In our
opinion, a new research input is now essential to over-
come this bias, to provide new efficacy and safety data on
the role of Pidotimod in preventing ARTIs in childhood.
New evidences on mechanisms of action of Pidotimod
Recently, research focused on one of these compounds,
Pidotimod, has attempted to better clarify and define its
mechanism of action both in vitro and in vivo. Pidoti-
mod (3-L-pyroglutamyl-L-thiaziolidine-4carboxylic acid)
is a synthetic dipeptide molecule with immunomodulatory
properties [14]. It is a highly purified molecule with high
reproducibility among batches. It is rapidly absorbed by
the gastrointestinal tract, with a bioavailability of 45% not
influenced by food and is eliminated unmodified via renal
excretory mechanisms [15]. The safety profile of Pidotimod
is good; no serious adverse events were reported in human
studies except for one case of suspected Henoch-Schönlein
purpura [16]. However, no other association with auto-
immune diseases have been reported so far.
In vitro studies in both animal and human specimens
have shown that Pidotimod has an immunomodulatory
activity on both innate and adaptive immune responses.
Pidotimod induces dendritic cell (DC) maturation, upre-
gulates the expression of HLA-DR and co-stimulatory
molecules CD83 and CD86, stimulates DCs to release
pro-inflammatory molecules, driving T cell proliferation
and differentiation towards a Th1 phenotype, enhances
natural killer cell functions, inhibits thymocyte apop-
tosis, and promotes phagocytosis [17-19]. More recently,
Carta et al. showed that Pidotimod induced in vitro
cellular changes that are potentially useful in enhancing
the capability of the host to fight respiratory infections
[20]. Through different effects on extracellular-signal-
regulated kinase (ERK1/2) and nuclear factor-kappa B
(NF-kB), Pidotimod increases the expression of toll-like
receptor 2 proteins (surface molecules involved in the
initiation of the innate response to infectious stimuli).
The lack of effect on intercellular adhesion molecule
(ICAM)-1 expression, the receptor for rhinovirus, and
on interleukin (IL)-8 release, the potent chemotactic fac-
tor for neutrophils (usually present at sites of infection),
may represent protective functions from infections. The au-
thors concluded that Pidotimod seemed to modulate airway
epithelial cell functions involved in host-virus interac-
tions, possibly through NF-kB activation.
Studies performed using in vivo and in vitro (animal
and cellular) experimental model systems are essential
for identifying the biological mechanisms of action of
Pidotimod, based on the assumption that these bio-
logical models have known ability to predict humanresponses. In spite of the encouraging results coming
from in vitro studies, to date, in vitro systems do not
predict all aspects of the mechanisms of action of a
drug. Thus, a combination of in vitro and human studies
is required for better characterisation of the efficacy of
Pidotimod.
A recent example of bridging the gap between preclin-
ical and clinical research was provided by Zuccotti et al.
in a study conducted on children with Down syndrome,
a population who frequently experiences ARTIs [21].
The authors randomised a cohort of subjects to receive
Pidotimod orally or placebo and analysed immune pa-
rameters before and after the injection of seasonal
2011–2012 virosomal adjuvanted influenza vaccine. They
found that the use of Pidotimod was associated with the
upregulation of a number of genes involved in the acti-
vation of innate immune responses and in antimicrobial
activity. Moreover, the ratio of flu-specific immuno-
globulin G1/G3 (IgG1/IgG3) was skewed in Pidotimod-
treated individuals, suggesting a preferential activation of
complement-dependent effector mechanisms. Although
preliminary, these data suggest that Pidotimod can poten-
tiate the beneficial effect of immunisation, possibly resulting
in a stronger activity of both innate and adaptive immune
responses.
Clinical issues
Up to now, clinical research on Pidotimod has mainly
focused on the prevention and treatment of ARTIs in
childhood. Studies conducted in the 1990s have shown
that this compound seems to have a beneficial effect in
children, reducing the number of ARTI, the number of
days of fever, and the severity of the signs and symptoms
of acute episodes [22-27]. A significant reduction in use
of antibiotics, antipyretic drugs, and symptomatic drugs,
and absence from school/nursery school and caregiver
absenteeism was also observed [22-27]. More recently, a
randomised trial has suggested that Pidotimod therapy is
a reliable, simple, and safe approach to treat children
with recurrent respiratory infections and it can reduce
the frequency of such infections as a result of improve-
ment of the ciliary respiratory epithelium [28].
A Cochrane meta-analysis that included all comparative
randomised controlled trials that enrolled participants
less than 18 years of age showed that immunostimulants
reduced the incidence of ARTIs by 40% on average in
susceptible children [29]. However, some bias such as the
heterogeneity of subjects recruited in trials in terms of
sample size, age, confounding factors (eg, concomitant
asthma or allergy, number of siblings, smokers at home,
seasons during the study, time and timing of attendance
at daycare centre), duration of the intervention, and mis-
used statistical tests limits the strength of conclusions of
the majority of studies.
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Certainly the improvement of research methodology in
the last 20 years and the acquired knowledge in various
fields of clinical immunology should be the starting
point for research on Pidotimod. Preclinical research will
continue to be essential to better understand the mecha-
nisms of action of this compound. However, in vivo
studies, especially randomised double-blind controlled
trials, are necessary to establish the role of Pidotimod in
preventing ARTIs in paediatric age.
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